Goserelin

Goserelin is a gonadorelin analog with similar effects, and was approved for
marketing in France in 1987. Goserelin is an analog of luteinizing hormone-
releasing hormone, long-term use of this product can inhibit the synthesis of
pituitary luteinizing hormone, thus causing a decline in serum testosterone in
men and serum estradiol in women, and after discontinuation of this effect can
be reversed, the initial use of this product can temporarily increase the
concentration of serum testosterone in men and serum estradiol in women. In
male patients, serum testosterone concentrations fall to depot levels about 21
days after the first injection of this drug and are maintained at these levels
during subsequent therapy, which results in regression of prostate tumors and
improvement of symptoms in most patients. In female patients, serum estradiol
concentrations are suppressed about 21 days after initial administration and
maintained at postmenopausal levels every 28 days of subsequent therapy. The
half-life of the product is 2 to 4 hours, which will increase in patients with
renal insufficiency. It is used for endometriosis, hormone-treatable prostate
cancer, and breast cancer in premenopausal and perimenopausal women.

Brand: Soarwin
CAS No.: 65807-02-5
Molecular Formula: C59H84N18O14
Density: 1.50±0.1 g/cm3(Predicted)
Storage: −20°C

Minimum Order: 1 bags